Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 15/20 | 0.51 |
| ▸ | FLT3 | P36888 | 8/20 | 0.51 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13736995 | 0.89 | FLT3 (0.55) | KITFLT3 | |
| SCHEMBL13737545 | 0.86 | KIT (0.52) | KITFLT3PDPK1 | |
| SCHEMBL13736452 | 0.86 | KIT (0.51) | KITFLT3 | |
| SCHEMBL13736416 | 0.86 | KIT (0.54) | KITFLT3 | |
| SCHEMBL13736786 | 0.78 | KIT (0.55) | KITFLT3MAOAROCK2 | |
| SCHEMBL13736123 | 0.77 | KIT (0.53) | KITFLT3 | |
| SCHEMBL11963147 | 0.77 | MAOA (0.51) | FLT3PDPK1MAOACDK2 | |
| SCHEMBL11963403 | 0.76 | IKBKE (0.54) | FLT3MAOAGSK3B | |
| SCHEMBL11963297 | 0.76 | CDC7 (0.50) | PDPK1CDC7ROCK2MAP4K4PIM1 | |
| SCHEMBL216014 | 0.74 | CNR2 (0.54) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-11-19 | — | — | US | disclosed |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-10-11 | — | — | US | disclosed |
| US-10028934-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-07-24 | — | — | US | disclosed |
| US-9597317-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-03-21 | — | — | US | disclosed |
| EP-2707359-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-11-30 | — | — | EP | disclosed |
| US-20160311776-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-27 | — | — | US | disclosed |
| US-20160310465-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-27 | — | — | US | disclosed |
| US-9408850-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-08-09 | — | — | US | disclosed |
| US-20140080807-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-03-20 | — | — | US | disclosed |
| EP-2707359-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-03-19 | — | — | EP | disclosed |
| WO-2012152763-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080807-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | KIT 631/4885FLT3 209/4885PDPK1 34/4885 |
| US-20160310465-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | KIT 669/4885FLT3 299/4885PDPK1 34/4885 |
| US-10028934-B2 | Substituted indazole derivatives active as kinase inhibitiors | MAP3K20, MAP3K1, MAP3K5 | KIT 669/4885FLT3 299/4885PDPK1 34/4885 |
| US-20160311776-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | KIT 669/4885FLT3 299/4885PDPK1 34/4885 |
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | MAP3K20, MAP3K1, MAP3K5 | KIT 669/4885FLT3 299/4885PDPK1 34/4885 |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | KIT 669/4885FLT3 299/4885PDPK1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.